Key result
Nonfunctional adrenal incidentaloma is linked to ~45% lower flow-mediated dilation and increased metabolic syndrome.
Why the study?
It is unclear whether nonfunctional adrenal incidentaloma increases the risk of atherosclerosis and metabolic syndrome or is more frequent in patients with cardiometabolic risk factors.
Does nonfunctional adrenal incidentaloma impair endothelial function and increase the prevalence of metabolic syndrome compared to matched controls?
Case-Control (n=105)
Does nonfunctional adrenal incidentaloma impair endothelial function and increase the prevalence of metabolic syndrome compared to matched controls?
Odds Ratio: 10
Absolute Event Rate: 7.1% vs 12.9%
p-value: p=<0.02
Nonfunctional adrenal incidentalomas are associated with impaired endothelial function and a higher prevalence of metabolic syndrome, independent of traditional cardiometabolic risk factors.
Observational link to endothelial dysfunction and metabolic syndrome warrants caution; hypothesis-generating and should not yet change incidentaloma management.
BACKGROUND: It is not clear whether nonfunctional adrenal incidentaloma (NFA) increases the risk of atherosclerosis and metabolic syndrome or whether this type of adrenal tumor has been found more frequently in patients with cardiometabolic risk factors. We aimed to determine the effects of NFA on cardiometabolic risk factors and endothelial function and to compare the patients with a 1:1 cardiometabolic risk factor matched control group. METHODS: Thirty-five patients with NFA were studied, and 35 body mass index-, age-, and sex-matched subjects were regarded as group 2 controls. Thirty-five cardiometabolic risk factors-matched subjects were then regarded as group 3 controls. RESULTS: Patients with NFA had significantly lower flow-mediated dilation (FMD)-a parameter for endothelial function-measurements compared with groups 2 and 3 (7.1 +/- 2.9% vs. 12.9 +/- 3.8% and 13.5 +/- 4.5%; P < 0.02). Frequency of metabolic syndrome was also significantly higher in NFA patients than in control groups 2 and 3 (31.4, 5.7, and 20.0%, respectively; P < 0.05). Age (Odds Ratio [OR] = 2.9), total cholesterol (OR = 2.3), and presence of adrenal incidentaloma (OR = 10) were significant independent predictors of lower FMD (P < 0.05 for all). CONCLUSIONS: Patients with NFA have increased prevalence of metabolic syndrome and impaired endothelial function compared with 1:1 cardiometabolic risk factor-matched controls.
No takes yet. Share an insight, caveat, or question.
Erbil et al. (2009) conducted a case-control in Nonfunctional adrenal incidentaloma (n=105). Nonfunctional adrenal incidentaloma vs. Matched controls was evaluated on Flow-mediated dilation (FMD) (OR 10, p=<0.02). Nonfunctional adrenal incidentaloma was associated with significantly lower flow-mediated dilation (7.1% vs 12.9% and 13.5%; P<0.02) and increased prevalence of metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: